Cat. No.: HY-15725

Copy Link Print Information

CDDO-Im

(Synonyms: RTA-403; TP-235; CDDO-Imidazolide)

12 Cited Publications

고객리뷰

Based on 12 publication(s) in Google Scholar

CDDO-Im (RTA-403) is an activator of Nrf2 and PPAR, with K_is of 232 and 344 nM for PPARα and PPARγ.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity: 99.30%
CAS No.: 443104-02-7
화학식: C₃₄H₄₃N₃O₃
분자량:541.72

보관:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

CDDO-Im Chemical Structure

CAS No.: 443104-02-7

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (12)
용액&용해도
- In Vitro
- In Vivo
Protocol
순도&문서
References
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

CDDO-Im (RTA-403) is an activator of Nrf2 and PPAR, with K_is of 232 and 344 nM for PPARα and PPARγ^[1]^[2].

IC₅₀ & Target^[1]^[2]

PPARα

232 nM (Ki)

PPARγ

344 nM (Ki)

Nrf2

All PPAR Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
BEL-7404 tumor cell line	IC₅₀	0.99 μM Compound: CDDO-Im	Antiproliferative activity against human Bel7404 cells after 72 hrs by CCK8 assay Antiproliferative activity against human Bel7404 cells after 72 hrs by CCK8 assay	[PMID: 25992974]
BXPC-3	IC₅₀	1.5 μM Compound: CDDO-Im	Antiproliferative activity against human BxPC3 cells after 72 hrs by CCK8 assay Antiproliferative activity against human BxPC3 cells after 72 hrs by CCK8 assay	[PMID: 25992974]
DU-145	IC₅₀	0.69 μM Compound: CDDO-Im	Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay	[PMID: 25992974]
HT-29	EC₅₀	2.1 μM Compound: 18	Anti-necroptotic activity in human HT-29 cells assessed as inhibition of TNFalpha/SM-164/Z-VAD-fmk (TSZ)-induced necroptosis by measuring increase in cell viability measured after 12 hrs by celltiter-glo luminescent cell viability assay Anti-necroptotic activity in human HT-29 cells assessed as inhibition of TNFalpha/SM-164/Z-VAD-fmk (TSZ)-induced necroptosis by measuring increase in cell viability measured after 12 hrs by celltiter-glo luminescent cell viability assay	[PMID: 33248849]
L929	EC₅₀	1.46 μM Compound: 18	Anti-necroptotic activity in mouse L929 cells assessed as inhibition of TNFalpha/Z-VAD-fmk (TZ)-induced necroptosis by measuring increase in cell viability measured after 12 hrs by celltiter-glo luminescent cell viability assay Anti-necroptotic activity in mouse L929 cells assessed as inhibition of TNFalpha/Z-VAD-fmk (TZ)-induced necroptosis by measuring increase in cell viability measured after 12 hrs by celltiter-glo luminescent cell viability assay	[PMID: 33248849]
NCI-H460	IC₅₀	0.42 μM Compound: CDDO-Im	Antiproliferative activity against human H460 cells after 72 hrs by CCK8 assay Antiproliferative activity against human H460 cells after 72 hrs by CCK8 assay	[PMID: 25992974]
RAW	IC₅₀	1 nM Compound: CDDO-Im	Inhibition of interferon gamma-stimulated NO production in RAW 264.7 cells after 24 hrs Inhibition of interferon gamma-stimulated NO production in RAW 264.7 cells after 24 hrs	[PMID: 17367124]
RAW264.7	IC₅₀	0.6 nM Compound: CDDO-Im	Inhibition of NO production in INFgamma-stimulated mouse RAW264.7 cells measured after 24 hrs by Griess reaction method Inhibition of NO production in INFgamma-stimulated mouse RAW264.7 cells measured after 24 hrs by Griess reaction method	[PMID: 21441026]
RAW264.7	IC₅₀	1 nM Compound: CDDO-Im	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of IFN-gamma induced NO production after 24 hrs by Griess reaction Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of IFN-gamma induced NO production after 24 hrs by Griess reaction	[PMID: 21361338]
RAW264.7	IC₅₀	1 μM Compound: 42; CDDO-Im	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of nitric oxide production Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of nitric oxide production	[PMID: 28754470]

In Vitro

CDDO-Im is highly active in suppressing cellular proliferation of human leukemia and breast cancer cell lines (IC₅₀ approximately 10-30 nM). In U937 leukemia cells, CDDO-Im also induces monocytic differentiation as measured by increased cell surface expression of CD11b and CD36^[1]. Treatment with CDDO-Im elevates protein levels of Nrf2, a transcription factor previously shown to bind ARE sequences, and increases expression of a number of antioxidant and detoxification genes regulated by Nrf2^[2]. CDDO-Im is one of the most potent synthetic triterpenoids shown to induce growth inhibition and apoptosis in various human cancer cells, including multiple myeloma, lung, pancreas and breast cancer. CDDO-Im treatment markedly induces cell cycle arrest at G2/M-phase and apoptosis in the triple-negative breast cancer cell lines, SUM159 and MDA-MB-231. The CD24 /EpCAM+ cells in SUM159 tumorspheres are significantly inhibited by CDDO-Im treatment. CDDO-Im also significantly decreases sphere forming efficiency and tumorsphere size in both primary and secondary sphere cultures^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

CDDO-Im is a potent inhibitor of de novo inducible nitric oxide synthase expression in primary mouse macrophages. Moreover, CDDO-Im inhibits growth of B16 murine melanoma and L1210 murine leukemia cells in vivo. Injection of 10 nM (5.4 μg) of CDDO-Im almost completely blocks the ability of IFN-γ to induce iNOS, and treatment with as little as 1 nmol of CDDO-Im (0.54 μg) is partially effective^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 443104-02-7
Appearance Solid
분자량 541.72
화학식 C₃₄H₄₃N₃O₃
Color White to off-white
SMILES

CC(C)([C@]1([H])CC[C@@]([C@@]2(CC[C@]3(CCC(C)(C[C@@]3([H])[C@]24[H])C)C(N5C=CN=C5)=O)C)6C)C(C(C#N)=C[C@]1(C)C6=CC4=O)=O
Synonyms

RTA-403; TP-235; CDDO-Imidazolide
선적

Room temperature in continental US; may vary elsewhere.

보관

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (12)

All WBRT-PCRIn Vivo Efficacy StudyHistological Imaging/Staining

Sort by:

Journal Impact Factor

Redox Biol

Compensation for impaired sensing of selenoprotein deficiency by alternative cysteine residues in KEAP1. [Abstract]

2026 Jun 15:95:104263. PMID: 42308694

CDDO-Im purchased from MedChemExpress. Usage Cited in: Redox Biol. 2026 Jun 15:95:104263. [Abstract]

Relative Nqo1, Gstm1, and Gclc mRNA levels were analyzed by RT-qPCR in the livers of 2-week-old Keap1^{C226S&C613S homo}:Trsp^fl/fl:AlbCre mice 24 h after a single oral administration of CDDO-Im (30 μmol/kg). CDDO-Im significantly increased the expression of all three genes compared with vehicle.

CDDO-Im purchased from MedChemExpress. Usage Cited in: Redox Biol. 2026 Jun 15:95:104263. [Abstract]

Survival of Keap1^{C226S&C613S homo}:Trsp^fl/fl:AlbCre mice orally administered CDDO-Im (30 μmol/kg; three times per week from 1 to 6 weeks of age) or vehicle was monitored for 6 weeks. Long-term CDDO-Im administration markedly improved survival, with approximately 80% of the mice surviving to 6 weeks of age.

CDDO-Im purchased from MedChemExpress. Usage Cited in: Redox Biol. 2026 Jun 15:95:104263. [Abstract]

Representative H&E-stained liver sections are shown from a 3-week-old vehicle-treated mouse and 6-week-old CDDO-Im-treated Keap1^{C226S&C613S homo}:Trsp^fl/fl:AlbCre mice under the regimen of CDDO-Im (30 μmol/kg; p.o.; three times per week beginning at 1 week of age). CDDO-Im-treated mice exhibited normal liver histology and much lower ALT level, whereas the representative vehicle-treated mouse showed extensive hepatocyte death and elevated plasma ALT level.
Redox Biol

Sensor systems of KEAP1 uniquely detecting oxidative and electrophilic stresses separately In vivo. [Abstract]

2024 Nov:77:103355. PMID: 39307045

CDDO-Im purchased from MedChemExpress. Usage Cited in: Redox Biol. 2024 Nov:77:103355. [Abstract]

NRF2 and NQO1 protein levels were analyzed by western blotting in the livers of 6–8-week-old male Keap1^+/+, Keap1^{C226S&C613S homo}, and Keap1^{C151S homo} mice 24 h after a single oral administration of CDDO-Im (30 μmol/kg). CDDO-Im induced accumulation of nuclear NRF2 in Keap1^+/+ and Keap1^{C226S&C613S homo} mice, whereas the induction was markedly reduced in Keap1^{C151S homo} mice.

CDDO-Im purchased from MedChemExpress. Usage Cited in: Redox Biol. 2024 Nov:77:103355. [Abstract]

Relative Nqo1 and Gstm1 mRNA levels were analyzed by RT-qPCR in the livers of 6–8-week-old male Keap1^+/+, Keap1^{C226S&C613S homo}, and Keap1^{C151S homo} mice 24 h after a single oral administration of CDDO-Im (30 μmol/kg). CDDO-Im induced Nqo1 and Gstm1 expression in Keap1^+/+ and Keap1^{C226S&C613S homo} mice, whereas the induction was significantly diminished in Keap1^{C151S homo} mice.
Cell Death Differ

Blockage of PPARγ T166 phosphorylation enhances the inducibility of beige adipocytes and improves metabolic dysfunctions. [Abstract]

2023 Mar;30(3):766-778. PMID: 36329235
Free Radic Biol Med

Establishment of Neh2-Cre:tdTomato reporter mouse for monitoring the exposure history to electrophilic stress. [Abstract]

2022 Nov 20;193(Pt 2):610-619. PMID: 36368569
Environ Pollut

Exposure to tris(1,3-dichloro-2-propyl) phosphate (TDCPP) induces vascular toxicity through Nrf2-VEGF pathway in zebrafish and human umbilical vein endothelial cells. [Abstract]

2019 Apr:247:293-301. PMID: 30685670
Eur J Med Chem

Discovery of bardoxolone derivatives as novel orally active necroptosis inhibitors. [Abstract]

2021 Feb 15:212:113030. PMID: 33248849
Gerontology

The Role of Nrf2 in D-Galactose-Induced Cardiac Aging in Mice: Involvement of Oxidative Stress. [Abstract]

2021;67(1):91-100. PMID: 33271531
Exp Neurol

CRHR1 antagonist alleviated depression-like behavior by downregulating p62 in a rat model of post-stroke depression. [Abstract]

2024 Aug:378:114822. PMID: 38823676
Food Chem Toxicol

Acute lung inflammation induced by zinc oxide nanoparticles: Evolution and intervention via NRF2 activator. [Abstract]

2022 Apr:162:112898. PMID: 35247504
Toxicol In Vitro

Gastrodin protects against glutamate-induced ferroptosis in HT-22 cells through Nrf2/HO-1 signaling pathway. [Abstract]

2020 Feb:62:104715. PMID: 31698019
Baylor University

2025.
bioRxiv

2025 April 14.

용액&용해도

In Vitro:

DMSO : 50 mg/mL (92.30 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8460 mL

9.2299 mL

18.4597 mL

5 mM

0.3692 mL

1.8460 mL

3.6919 mL

10 mM

0.1846 mL

0.9230 mL

1.8460 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (4.61 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (4.61 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.61 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 4

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline

Solubility: 2.5 mg/mL (4.61 mM); Suspended solution; Need ultrasonic

Protocol 5

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (4.61 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[3]

CDDO-Im is dissolved in DMSO. SUM159 and MDA-MB-231 cells are seeded into each well of 96-well plates (1,000 cell/well) and treated the next day with vehicle control or CDDO-Im (1, 10, 50, 100 and 200 nM) for given incubation time. The absorbance is measured with a spectrophotometer to determine cell proliferation rate^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Mice: Mice are injected i.p. with thioglycollate, and the resulting resident peritoneal macrophages are activated 3 days later with an i.p. injection of IFN-γ. CDDO and CDDO-Im are injected i.p. 30 min after IFN-γ. Macrophages are harvested 10 h later, cultured for 12 h, and then assayed for expression of iNOS protein and production of nitric oxide (NO)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Place AE, et al. The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res. 2003 Jul;9(7):2798-806. [Content Brief]

[2]. Liby K, et al. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res. 2005 Jun 1;65(11):4789-98. [Content Brief]

[3]. So JY, et al. A synthetic triterpenoid CDDO-Im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancer. PLoS One. 2014 Sep 17;9(9):e107616. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.8460 mL	9.2299 mL	18.4597 mL	46.1493 mL
	5 mM	0.3692 mL	1.8460 mL	3.6919 mL	9.2299 mL
	10 mM	0.1846 mL	0.9230 mL	1.8460 mL	4.6149 mL
	15 mM	0.1231 mL	0.6153 mL	1.2306 mL	3.0766 mL
	20 mM	0.0923 mL	0.4615 mL	0.9230 mL	2.3075 mL
	25 mM	0.0738 mL	0.3692 mL	0.7384 mL	1.8460 mL
	30 mM	0.0615 mL	0.3077 mL	0.6153 mL	1.5383 mL
	40 mM	0.0461 mL	0.2307 mL	0.4615 mL	1.1537 mL
	50 mM	0.0369 mL	0.1846 mL	0.3692 mL	0.9230 mL
	60 mM	0.0308 mL	0.1538 mL	0.3077 mL	0.7692 mL
	80 mM	0.0231 mL	0.1154 mL	0.2307 mL	0.5769 mL

Keywords

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

CDDO-Im

Covalent Screening Library

Antioxidant Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Anti-Breast Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Antidepressant Compound Library

Anti-Pulmonary Fibrosis Compound Library

Nuclear Receptor Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Bioactive Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Publications Citing Use of MedChemExpress (MCE) CDDO-Im

All PPAR Isoforms

Biological Activity

Chemical Information

Publications (12)

용액&용해도

Protocol

순도&문서

References

Help & FAQs

Complete Stock Solution Preparation Table

CDDO-Im Related Classifications

HY-15725 Related Classifications